Close Menu

NEW YORK – Agios submitted a supplemental new drug application on Monday to the US Food and Drug Administration for ivosidenib (Tibsovo) to treat IDH1-mutated bile duct cancer.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.